Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
Loading...
0 selected
Loading...
1 selected
0 selected
All post types✓
Portfolio updates✓
Stock lists✓
Research✓
News✓
All Content✓
Source feeds
Buzzberg Top 50
✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Jul 23 ◎
Jul 23 ◎
DGX
FMS
ELV
GH
NTRA
▾
HIGH
Management raised full-year guidance for the second time, citing strong organic growth driven by broad clinical demand, automation gains, and robust performance across channels.
"We now expect revenues to be between $11.95 billion and $12.05 billion, reflecting a growth rate of 8.3% to 9.2%. Reported EPS to be in a range of $9.97 to $10.17, and adjusted EPS in a range of $11.05 to $11.25."
DGX WATCH
Quest's partnership with Fresenius is driving volume and expanding its kidney testing portfolio, contributing to revenue growth.
"Our collaborations with Fresenius Medical Care continue to support growth in the quarter. Through this relationship, we have fostered new capabilities for serving nephrologists and other providers caring for the nearly 36 million people in"
FMS WATCH
Elevance's new coverage for Alzheimer's biomarkers expands reimbursed test volume for Quest, though AB4240 is not yet covered.
"Elevance recently added coverage for certain blood-based biomarker tests for Alzheimer's. I think that makes it one of, if not the first, major payer to do so."
ELV WATCH
Quest serves as a collection and testing partner for Guardant's Shield colon cancer screening test, but management declined to disclose volumes.
"we offer it on our menu and we offer to do draws at a price, obviously. Garden pays us for that."
GH WATCH
Quest's Haystack MRD test received New York State approval; management noted only one other company has a tumor-informed MRD test cleared by NY State, implying a competitive edge. — Positions Quest as a leader in the MRD space alongside Natera (Signatera), potentially pressuring Guardant's Reveal and other naïve tests.
"I believe there's only one other company that has approval from New York State from a tumor-informed standpoint."
NTRA WATCH
HIGH
08:30
Apr 21 ◎
Apr 21 ◎
DGX
FMS
GH
LH
▾
HIGH
Management raised full-year revenue and EPS guidance after a strong Q1 driven by broad-based organic growth, advanced diagnostics, and productivity improvements from automation and AI.
"Given our strong first quarter momentum and continued strategic focus, we are raising our revenue and EPS guidance for the year."
DGX WATCH
Quest provides lab testing for Fresenius dialysis clinics; this relationship contributes significantly to volume but has a dilutive effect on revenue per requisition.
"Fresenius Medical Care and Corwell Health contributed approximately 7% to organic volume growth in the quarter."
FMS WATCH
Quest will collect blood samples for Guardant's colon cancer test and list it on their menu; early adoption is underway but volumes are not yet material.
"we announced a partnership to distribute, do blood collections for the GARDENT colon cancer CRC test."
GH WATCH
Quest management noted that health plans are increasingly questioning paying hospital outreach labs 200-300% of the rates paid to independent labs, signaling a shift in pricing power away from hospital systems. — If health plans normalize rates, it could benefit Quest and LabCorp by reducing hospital competition on price, potentially accelerating hospital lab outsourcing.
"why am I paying these health system labs 2% to 300% of what we pay to the leading independents across the country?"
LH WATCH
HIGH
08:30
Feb 10 ◎
Feb 10 ◎
DGX
FMS
ELV
GRAL
GH
▾
HIGH
Management issued guidance for 6-7% revenue growth and expanding margins, backed by strong organic volume, advanced diagnostics momentum, and consumer channel growth, despite weather headwinds.
"Our 2026 guidance reflects our continued confidence in our business strengths and market fundamentals supporting enduring interest in our diagnostic innovations."
DGX WATCH
Quest has scaled operations for Fresenius, indicating strong demand for dialysis testing services; Fresenius benefits from Quest's expanded capacity and water purity testing.
"we scaled our lab testing to serve more than 200,000 patients at Fresenius Medical Care's dialysis centers in the United States."
FMS WATCH
Re-inclusion in Elevance's networks is driving volume share gains, positive for Quest's organic growth trajectory in those states.
"we got back into network with Elevance in several key states last year, Nevada, Colorado, Georgia, and Virginia."
ELV WATCH
Quest provides phlebotomy logistics for Grail's multi-cancer early detection test, representing a modest but growing revenue stream and validating Grail's clinical deployment.
"we have a partnership with Grail. We will do the blood draws for Grail."
GRAL WATCH
Quest will provide draw services for Guardant's colon cancer blood test, potentially expanding Quest's consumer and oncology volume.
"we did announce a partnership to draw for the garnet colon cancer-based blood screening test"
GH WATCH
HIGH
08:30
Oct 21 ◎
Oct 21 ◎
DGX
FMS
GH
ELV
CRWD
▾
HIGH
Quest raised full-year guidance on broad-based demand, organic growth acceleration, and margin expansion, signaling sustained momentum.
"Given our strong performance year to date, we are again raising our full year 2025 guidance."
DGX WATCH
Quest has won a large enterprise agreement to serve Fresenius dialysis centers, adding revenue and utilizing excess capacity.
"We also began to roll out clinical lab testing to Fresenius Medical Care's dialysis centers, which serve about 200,000 dialysis patients annually in the U.S."
FMS WATCH
Quest is distributing Guardant's colorectal cancer screening test, expanding Guardant's reach into primary care.
"collaborations that leverage Quest's national scale in phlebotomy and connectivity to broaden access to cancer screening liquid biopsy tests, including garden health shields tests for colorectal cancer"
GH WATCH
Quest regained network status with a major health plan, driving volume recovery in those states.
"we're back in network with Elevance in some key states, Nevada, Colorado, and Virginia"
ELV WATCH
CrowdStrike's IT outage created a prior-year volume headwind for Quest, providing a 50 bps comp benefit in the current quarter.
"the impact of weather and the CrowdStrike global IT outage was a headwind on our volume in the third quarter last year"
CRWD WATCH
Quest's Alzheimer's blood test (AD-Detect) revenue more than doubled in Q3 following new clinical guidelines, signaling rapid market adoption and potential pressure on amyloid PET and CSF testing. — Blood-based biomarkers are displacing more expensive imaging and CSF tests, which could reduce volumes for PET tracer suppliers and CSF assay platforms.
"In brain health, demand for our Quest AD Detect blood tests for Alzheimer's disease accelerated and more than doubled in the third quarter."
GEHC WATCH
ILMN WATCH
HIGH
Choose Sources
Loading sources...